PQ Bypass secures $60m equity financing to advance PAD treatment
PQ Bypass stated that the funds will be used by the company to advance its technology for the treatment of long blockages in leg arteries caused by peripheral
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XPQ Bypass stated that the funds will be used by the company to advance its technology for the treatment of long blockages in leg arteries caused by peripheral
BioWave products are Professional Athlete proven and US Military trusted and is currently used by most NFL, NBA, NHL, and MLB teams, 160+ college programs, over 80 VA
Created last September by Deerfield Management (Deerfield) and Stanton Rowe, CEO of NXT Biomedical, this next-generation medical device incubator is committed to developing transformational technologies to address significant unmet
This innovative collaboration will set the stage to substantially increase the availability and speed of personalized orthopedic care for patients with complex orthopedic conditions in the United States.
The Duo System features the only implant on the market that combines PEEK, titanium, and graft containment mesh elements. The implant, which is filled with bone post-insertion, creates
Under the deal terms, the companies will partner on the use of Orbit Biomedical’s injection technology to deliver OpRegen to treat dry-AMD. Orbit Biomedical, founded last year in London,
Aulisa Medical stated that this product can help in not just monitoring vitals and alarm systems and address the changing healthcare landscape. The company’s line of vitals monitoring
ONM-100 is the first product from a platform based upon the OncoNano’s library of micelles that respond to pH variability. OncoNano Medicine regulatory affairs vice president Kathy Rath
The iLet is a pocket-sized, dual-chamber, autonomous, glycemic control system that mimics a biological pancreas by calculating and dosing insulin and/or glucagon as needed based on data from
Cesca Therapeutics has also formed new ThermoGenesis subsidiary, CARTXpress Bio, to focus on its CAR-TXpress cellular processing platform. BCC has taken 20% ownership in CARTXpress Bio, while the